BAGSV�RD, Denmark, Sept. 18, 2019 /PRNewswire/ --
Novo Nordisk announced today the results from two Ozempic(R) (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed:
- Ozempic(R) was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and body weight in people with type 2 diabetes uncontrolled on metformin.[1] - Ozempic (R) was superior to Victoza� (liraglutide 1.2 mg) in reducing HbA1c and body weight in people with type 2 diabetes.[2]
These data were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, and simultaneously published in The Lancet Diabetes & Endocrinology (SUSTAIN 8) and Diabetes and Metabolism (SUSTAIN 10).[1],[2]
"We are proud of the superior clinical profile of once-weekly Ozempic(R), as demonstrated through all the SUSTAIN clinical trials, and encouraged by these new data which further reinforce the value of Ozempic(R) for people with type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
These trials form part of the extensive SUSTAIN programme, a global clinical development programme that comprises more than 10 Phase 3 trials involving more than 10,065 adults with type 2 diabetes. To date, outcomes of SUSTAIN 1-7 and 9 have been published demonstrating Ozempic(R) is a best-in-class, efficacious and well-tolerated treatment option for people with type 2 diabetes.
SUSTAIN 8[1]
At 52 weeks, Ozempic(R) demonstrated a superior reduction in mean HbA1c of 1.5% compared to canagliflozin at 1.0%, from a baseline of 8.3%. In addition, 66.1% of people treated with Ozempic(R) achieved HbA1c treatment target
